GLAND PHARMA LIMITED

November 09, 2026

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Appointment of Chief Investment Officer for Gland Pharma International Pte. Ltd (Wholly-owned subsidiary of Gland Pharma Limited)

We would like to inform you that Mr. Xiao Le has been appointed as the Chief Investment Officer of Gland Pharma International Pte. Ltd., ('Gland Singapore') the Wholly-owned subsidiary of the Company, effective November 09, 2026.

Mr. Xiao Le will be responsible for exploring various investment opportunities and to improve M&A capability for Gland in the United States of America, China, Singapore and other countries.

Mr. Xiao Le shall be reporting to the CEO of Gland Singapore.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are given in **Annexure-A** enclosed herewith.

This is for your information and records.

Yours truly,
For Gland Pharma Limited

Pallerlamudi Sampath Kumar
Digitally signed by Pallerlamudi Sampath Kumar
DN: cn=Pallerlamudi Sampath Kumar, c=IN, o=Personal, email=sampath@glandpharma.com
Date: 2026.11.09 09:45:03 +05'30'

Sampath Kumar Pallerlamudi
Company Secretary and Compliance Officer

Encl: Annexure A

Annexure A

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD/I/3762/2026 dated January 30, 2026

Details of Mr. Xiao Le

SI. No	Particulars	Remarks
1	Reason for change & Date of Change	Mr. Xiao Le, has been appointed as the Chief Investment Officer of Gland Singapore, effective November 09, 2026.
2	Brief profile	Mr. Xiao Le has over 15 years of experience in investment and assets management in the sphere of medical devices, biopharma, Dx / Tools, healthcare services. He has a rich experience performing all kinds of roles including Chief Financial Officer for MegaRobo Technologies, Singapore; Director on the Board of Directors of CANbridge Pharmaceuticals, United States representing WuXi, Senior Director of M&A and Strategic investments for Wuxi AppTec, Director of Dimensions Capital, and various roles in Middleton Gardiner Group, LLC; NYSE, Bank of America Merrill Lynch, etc. He has worked in various countries like Singapore, China and the Unites States of America. Mr. Xiao Le holds a Bachelor's degree in Bio-engineering from The Johns Hopkins University and a Master's degree in Finance from The Massachusetts Institute of Technology.
3	Disclosure of relationships between director	Not Applicable
4	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/24, both dated June 20, 2018	Not Applicable